BUSINESSJul 9 · 07:34 UTCCNBC TOP

AstraZeneca stock dives 9% after heart drug trial misses target

AstraZeneca's stock fell 9% following a heart drug trial that failed to meet its target. The decline reflects investor disappointment over the unmet clinical trial objective.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

AstraZenecaorganizationheart drug trialtopicstock pricetopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHApr 28 · 17:23 UTC
Cancer Drug Developer Erasca Sinks by Record 55% After Patient Death
HEALTHJun 2 · 07:43 UTC
Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
BUSINESSJun 8 · 02:45 UTC
Asian shares drop after plunge in Big Tech stocks gives Wall St its worst day in months
BUSINESSJun 29 · 06:03 UTC
LatAm Pre-Open: Brazil Extends Record Run as Chips Keep Sliding
BUSINESSJun 10 · 02:55 UTC
China Healthcare Stocks Fall to Record Low Valuation on AI Drain